This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.
The primary objective of this study is to understand the evolution of initial treatment patterns among patients with early-stage (I-III) NSCLC.
Study Type
OBSERVATIONAL
Enrollment
3,000
Research Site
Beijing, China
RECRUITINGTreatment Patterns
Proportion of patients with different treatment regimens
Time frame: Up to 50 months
Proportion of unresected patients in SI/II/III
Proportion of patients who are unresected among SI/II/III NSCLC patients enrolled, respectively
Time frame: Up to 50 months
CRT rate in USIII
Proportion of patients who have CRT regimen among unresected SIII patients enrolled
Time frame: Up to 50 months
Treatment Duration
TKI treatment duration and discontinuation reason in EGFRm patients * Duration of treatment * Treatment discontinuation (time to discontinuation, and reason for discontinuation)
Time frame: Up to 50 months
Patterns of recurrence
Type of recurrence following initial treatment regimen (Loco-regional recurrence, distant recurrence, other)
Time frame: Up to 50 months
Guideline adoption rate
Resected EGFRm Stage IB-III * Proportion of patients received guideline recommended TKI adjuvant regimen among a. resected EGFRm Stage IB-III patients; b. patients with TKI adjuvant therapy Unresected Stage III * Proportion of patients received guideline recommended systemic IO and TKI regimens among patients who received CRT
Time frame: Up to 50 months
AstraZeneca Clinical Study Information Center
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.